Approximately 1 in 5 individuals in the United States alone will experience depression during their lifetime. Current guidelines suggest that monotherapy may be used as initial therapy for major depressive disorder, but what evidence exists suggesting that starting dual anti-depressant therapy may have better outcomes? Join your host, Geoff Wall as he discusses a recent meta-analysis regarding dual therapy in depression.  

The GameChanger:  

For initial therapy or patients who are non-respondent to previous treatment, dual anti-depressant therapy may have a small, but significant impact on treatment outcomes, specifically treatment efficacy.  

Show Segments 

00:00 – Introductions 

01:19 – Dual Therapy in Depression 

11:57 – Which Anti-Depressant Combination? 

15:27 – The GameChanger 

18:37 – Closing Remarks  

Host:
Geoff Wall, PharmD., BCPS, FCCP, CGP 
Professor of Pharmacy Practice, Drake University 
Internal Medicine/Critical Care, UnityPoint Health 

References and resources: 

Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis 

Redeem your CPE or CME credit here! 

• Pharmacist members 
• CME 

Need a membership? 

• Join for CPE Credit  
• Join for CME Credit 

Continuing Education Information: 

Learning Objectives: 

1. Describe which two classes of antidepressants had the highest remission rate when used together in this study  
2. Discuss the pros and cons of this meta-analysis including the studies' heterogeneity 

Dr. Wall is a member of the Janssen Speaker's Bureau. 

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-143-H01-P
Initial release date: 04/4/22
Expiration date: 04/4/2023

For more information https://www.ceimpact.com/podcast 

Follow CEimpact on Social Media:
LinkedIn
Instagram